Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

QR Code

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Salzman PM, Raoufinia A, Legacy S, Such P, Eramo A
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	long-acting injectable aripiprazole plasma concentrations dosing schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/ca5b79ce43c04b4b963ea261d0ea7795
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
par: McConnell SA, et autres
Publié: (2017)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
par: Madera JJ, et autres
Publié: (2019)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
par: Peters-Strickland T, et autres
Publié: (2019)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
par: Cuomo I, et autres
Publié: (2018)

Aripiprazole for late-life schizophrenia
par: Jeffrey Rado, et autres
Publié: (2010)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
par: Sajatovic M, et autres
Publié: (2018)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
par: Sajatovic M, et autres
Publié: (2018)

Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
par: Junli Zhu, et autres
Publié: (2021)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
par: Madera J, et autres
Publié: (2019)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
par: Dhiren Singh, et autres
Publié: (2009)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
par: Anand E, et autres
Publié: (2016)

Low-dose aripiprazole for refractory burning mouth syndrome
par: Umezaki Y, et autres
Publié: (2016)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
par: Citrome L, et autres
Publié: (2019)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
par: Ohnishi T, et autres
Publié: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

DEVELOPMENT OF A SIMPLE AND SPECIFIC UHPLC ASSAY FOR THE DETERMINATION OF ARIPIPRAZOLE AND DEHYDROARDPDPRAZOLE IN RAT PLASMA
par: YENICELI UĞUR,DUYGU, et autres
Publié: (2015)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
par: Zhi P, et autres
Publié: (2018)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
par: de Bartolomeis A, et autres
Publié: (2016)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
par: Chiu LL, et autres
Publié: (2019)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
par: Fitzgerald HM, et autres
Publié: (2021)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
par: Shao Q, et autres
Publié: (2015)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations
par: Mayerova M, et autres
Publié: (2018)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
par: Kishi T, et autres
Publié: (2016)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
par: Peters-Strickland T, et autres
Publié: (2016)

Long-acting reversible hormonal contraception
par: N. E. Dahan-Farkas, et autres
Publié: (2016)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
par: Suda A, et autres
Publié: (2018)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
par: Subramanian Madhusoodanan, et autres
Publié: (2008)

The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing
par: Lefan Jin, et autres
Publié: (2021)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Alcohol dependence is formed on the background of violations of mental adaptation
par: T. V. Agibalova, et autres
Publié: (2013)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)